Complete revascularization improves angina-related quality of life in patients who have ST-segment elevation myocardial infarction (STEMI) with multivessel coronary artery disease, a new COMPLETE substudy shows.
Both complete revascularization and culprit-lesion-only percutaneous coronary intervention (PCI) improved scores at 6months on the patient-reported Seattle Angina Questionnaire (SAQ). Four of the five subscales favored complete revascularization at 6months, and all five did so at study end, with a median follow-up of 3years.
Residual angina at study end was present in 12.5% of patients in the complete revascularization group and 15.7% in the culprit-only group (P= .013).
Subgroup analyses revealed the benefit was almost entirely in patients with tighter nonculprit lesions with at least 80% stenosis (Pfor interaction= .05), said Shamir Mehta, MD, Population Health and Research Institute, McMaster University and Hamilton Health Sciences, Ontario, Canada.
"Complete revascularization improves overall patient-reported health status in addition to its established benefit in reducing major cardiovascular events," he said during a featured clinical research session at the American College of Cardiology (ACC) 2022 Scientific Session.
"These data also provide new information for physicians and patients to consider in the context of shared decision making as it relates to coronary artery revascularization in patients with STEMI," Mehta added.
As previously reported, the landmark trial showed that complete revascularization reduced cardiovascular death and new myocardial infarction (MI), leading to a class1a recommendation for complete revascularization in the multisociety 2021 guideline for coronary artery revascularization. Its effect on angina-related quality of life, however, is unclear and hasn't previously been evaluated in a randomized trial, he said.
The trial enrolled 4041 patients with STEMI and multivessel disease who had undergone successful PCI of the culprit lesion but were found to have nonculprit lesions of at least 70% or a fractional flow reserve measurement of 0.80. Patients were then randomly assigned to complete revascularization of any additional angiographically significant nonculprit lesions or to no further revascularization. Among those allocated to intervention, 122 crossed over to culprit-lesion-only revascularization.
SAQ data were collected at baseline, 6months, and study end, with final data available from 86.8% of the complete revascularization group and 85.0% of the culprit-only group. Mean age of the study participants was 62years, 19% were female, and 19% had diabetes.
At baseline, 12% of patients reported weekly or daily angina but, importantly, 50% had no self-reported history of angina, Mehta pointed out.
The change in SAQ scores from baseline to 6months for the complete revascularization and culprit-only groups was as follows:
Angina frequency: 7.3 vs 6.4 (P= .039)
Physical limitation: 3.3 vs 3.3points (P= .18)
Treatment satisfaction: 0.7 vs 0.2points (P< .001)
Quality of life: 13.2 vs 11.5 (P< .001)
Summary score: 13.2 vs 11.5 (P< .001)
At a median of 3years, the change from baseline in the five subscales was:
Angina frequency: 9.8 vs 8.6 (P= .006)
Physical limitation: 4.2 vs 4.3 (P= .018)
Treatment satisfaction: 0.6 vs 0.2 (P= .028)
Quality of life: 16.3 vs 15.9 (P= .048)
Summary score: 9.8 vs 9.6 (P= .003)
When the researchers looked at total angina burden through follow-up, the absolute risk difference was 9% between the complete revascularization and culprit-only groups, with a number needed to treat of only 11 in patients with a new MI, ischemia-driven revascularization, unstable angina, or residual angina (19.8% vs 28.6%; P< .001).
Residual stenosis was reported among patients with less than 80% nonculprit-lesion stenosis in 11% with culprit-lesion-only PCI and in 14% with complete revascularization. Among those with 80% or greater nonculprit-lesion stenosis, however, 16.8% and 12.3%, respectively, reported residual angina (Pfor interaction= .017).
"The COMPLETE trial is the gift that keeps on giving," said Timothy Henry, MD, invited discussant for the trial and president of the Society for Cardiovascular Angiography& Interventions.
"I must admit that when I saw this substudy, I was a little bit surprised because, number one, there was crossover in the trial already, so that the absolute difference in revascularization between the two groups is relatively small," he said. "Number two, there are relatively low events: it's 15.7% vs 12.5% that still have angina, so the fact you still see a difference was a little surprising to me and your analysis is tremendous."
Given that there were patients who had over 80% stenosis in nonculprit lesions and residual angina, "should the crossover rates have been higher?" asked Henry, from Christ Hospital, Cincinnati.
In terms of major cardiovascular events, Mehta said, the benefit for the first coprimary outcome of CV death and new MI was really in patients with a tighter nonculprit lesion stenosis, but that the benefit for the second coprimary endpoint of ischemia-driven revascularization was in patients with lesser and greater degrees of stenosis.
"Here for patient-reported angina analysis, it appears that the benefit on angina specifically is really in patients with more severe nonculprit lesions," he said.
The COMPLETE trial was funded by the Canadian Institutes of Health Research, the Population Health Research Institute, AstraZeneca, and Boston Scientific. Mehta reports consultant fees/honoraria from Amgen and research/research grants from Abbott Laboratories. Henry reports consultant fees/honoraria from Abbott Vascular, Boston Scientific, and Chiesi.
American College of Cardiology (ACC) 2022 Scientific Session. Presented March2, 2022.
Follow Patrice Wendling on Twitter: @pwendl For more from theheart.org | Medscape Cardiology, follow us on Twitter and Facebook.
Continue reading here:
QOL Improves With Complete Revascularization After STEMI - Medscape
- Best 30 Cardiology in Secaucus, NJ with Reviews - YP.com - April 12th, 2018 [April 12th, 2018]
- Cardiology | Weill Cornell Medicine - April 14th, 2018 [April 14th, 2018]
- Cardiology Conferences 2018 | Cardiology Meetings 2018 ... - April 26th, 2018 [April 26th, 2018]
- Dr. Anil Goel, MD - Birmingham, MI - Cardiology & Clinical ... - April 26th, 2018 [April 26th, 2018]
- Clinical Physiology (Cardiology) MSc/PGDip | Middlesex ... - May 15th, 2018 [May 15th, 2018]
- Cardiology Conferences 2018 | Upcoming Cardiology ... - May 16th, 2018 [May 16th, 2018]
- Clinical Cardiology Section | Cleveland Clinic - May 27th, 2018 [May 27th, 2018]
- Journal of Clinical and Experimental Cardiology - Open ... - June 6th, 2018 [June 6th, 2018]
- Cardiology Summit 2018 | Cardiology Conferences | Heart ... - June 23rd, 2018 [June 23rd, 2018]
- Cardiology Clinical and Research Faculty Members ... - June 26th, 2018 [June 26th, 2018]
- Cardiology Conferences 2018 | Cardiology Congress 2018 ... - June 26th, 2018 [June 26th, 2018]
- About Us - New Jersey Cardiology Associates - July 8th, 2018 [July 8th, 2018]
- About Us - Ventura Clinical Trials - August 16th, 2018 [August 16th, 2018]
- Clinical Cardiology Made Ridiculously Simple: Michael A ... - August 22nd, 2018 [August 22nd, 2018]
- Clinical Cardiology - American Society of Preventive Cardiology - October 2nd, 2018 [October 2nd, 2018]
- Heart Surgery Hospital in india | Cardiology Treatment ... - October 7th, 2018 [October 7th, 2018]
- Clinical Cardiology - American Society of Preventive ... - December 3rd, 2018 [December 3rd, 2018]
- Guideline Clinical App - American College of Cardiology - December 7th, 2018 [December 7th, 2018]
- Journal of Clinical and Experimental Cardiology- Open ... - December 12th, 2018 [December 12th, 2018]
- Clinical Cardiology - Baptist Health - December 30th, 2018 [December 30th, 2018]
- Cardiology at Cancun: Topics in Clinical Cardiology - February 5th, 2019 [February 5th, 2019]
- Department of Cardiovascular Medicine, KU School of Medicine - March 10th, 2019 [March 10th, 2019]
- Towards Health Equality: Improving the Management of Cardiovascular Diseases in Women - International Atomic Energy Agency - September 21st, 2019 [September 21st, 2019]
- Lifetime Risk of PAD Varies by Race, but All Are Vulnerable to Traditional Risk Factors - TCTMD - September 21st, 2019 [September 21st, 2019]
- DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF - TCTMD - September 21st, 2019 [September 21st, 2019]
- Combining Nature and Technology, Luye Medical and Cleveland Clinic Join to Build a Future Hospital in Shanghai - Yahoo Finance - September 21st, 2019 [September 21st, 2019]
- Will Renal Denervation for Hypertension Rise Again? - Medscape - September 21st, 2019 [September 21st, 2019]
- Obstructive Sleep Apnea, Sleep Symptoms, and their Association with Cardiovascular Disease - DocWire News - September 21st, 2019 [September 21st, 2019]
- CNE expands pulmonary, sleep services with Brigham & Women's physicians - Warwick Beacon - September 21st, 2019 [September 21st, 2019]
- What I Am Most Looking Forward to at TCT 2019 - TCTMD - September 21st, 2019 [September 21st, 2019]
- Serelaxin Not Linked to CV Mortality Reduction in Patients Hospitalized for Acute HF - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- Sacubitril-Valsartan Not Linked to Lower Hospitalization Risk, CV Death in HFpEF - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- FDA clears multiuse angiography systems from Siemens Healthineers - DOTmed HealthCare Business News - September 21st, 2019 [September 21st, 2019]
- Balloon Pulmonary Angioplasty Effective for Chronic Thromboembolic PH - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- RWJBarnabas Health, St. Luke's University Health launch clinical affiliation - FierceHealthcare - September 21st, 2019 [September 21st, 2019]
- Bilirubin: A Novel Indicator of Infective Endocarditis Adverse Outcomes - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS - TCTMD - September 21st, 2019 [September 21st, 2019]
- Community-based Care Model Reduces CVD Risk - Managed Healthcare Executive - September 21st, 2019 [September 21st, 2019]
- American College of Cardiology Steps Up: Equal Pay, Opportunities for All - TCTMD - September 21st, 2019 [September 21st, 2019]
- FDA Approves Novo Nordisk's Oral Semaglutide, First GLP-1 in Pill Form - AJMC.com Managed Markets Network - September 21st, 2019 [September 21st, 2019]
- A New Drug for HF? DEFINE-HF Bolsters Dapagliflozin Cardio Cred - Medscape - September 21st, 2019 [September 21st, 2019]
- Seeking Synergy: Bringing Cardiology into Your Enterprise Imaging Strategy - Health Imaging - September 21st, 2019 [September 21st, 2019]
- TCT 2019 Day Two: Transcatheter Valves, New and Old - TCTMD - September 30th, 2019 [September 30th, 2019]
- Transcatheter Options Best for Tricuspid Regurgitation in Matched Registry Analysis - TCTMD - September 30th, 2019 [September 30th, 2019]
- Bypass Surgery and Coronary Stenting Yield Comparable 10-Year Survival - Diagnostic and Interventional Cardiology - September 30th, 2019 [September 30th, 2019]
- TAVR Improves Health Status Over Surgery in Low-Risk Patients at 1 Year: PARTNER 3 - TCTMD - September 30th, 2019 [September 30th, 2019]
- Eidos Therapeutics to Present Interim Analysis of the Ongoing Phase 2 Open-Label Extension Study of AG10 in Patients with TTR Amyloid Cardiomyopathy... - September 30th, 2019 [September 30th, 2019]
- Off Script: The New Gatekeepers of Procedural Education - TCTMD - September 30th, 2019 [September 30th, 2019]
- Study Shows Safety and Efficacy of Near Infrared Spectroscopy (NIRS) Imaging to Identify Patients and Plaques at an Increased Risk for MACE - BioSpace - September 30th, 2019 [September 30th, 2019]
- The Heart of the Matter: Cardiovascular Fitness in Horses - United States Eventing Association - September 30th, 2019 [September 30th, 2019]
- Google parent Alphabet hires former FDA head Robert Califf to lead health strategy and policy - FierceHealthcare - September 30th, 2019 [September 30th, 2019]
- Inclisiran Benefits Patients With Familial Hypercholesterolemia and ASCVD - The Cardiology Advisor - September 30th, 2019 [September 30th, 2019]
- AUGUSTUS: Best Benefit With Apixaban, P2Y12 Inhibitor Dual Therapy - Medscape - September 30th, 2019 [September 30th, 2019]
- New TAVR System Safe and Effective for High-Risk Surgical Patients with Severe Aortic Stenosis - Newswise - September 30th, 2019 [September 30th, 2019]
- Dapagliflozin Improves Heart Failure-Related Health Status in HFrEF - The Cardiology Advisor - September 30th, 2019 [September 30th, 2019]
- Remote Ischemic Conditioning Did Not Improve 12 Month Clinical Outcomes After STEMI - The Cardiology Advisor - September 30th, 2019 [September 30th, 2019]
- Insights from the European Society of Cardiology congress | Speaking of Medicine - PLoS Blogs - September 30th, 2019 [September 30th, 2019]
- Smokers Have More Pulmonary Emboli, Leading to Higher Hospital Readmission Rates | - Diagnostic and Interventional Cardiology - October 22nd, 2019 [October 22nd, 2019]
- AZ's Farxiga gets heart failure prevention okay from FDA - PMLiVE - October 22nd, 2019 [October 22nd, 2019]
- Bayer Announces Recipients of the Pulmonary Hypertension Accelerated Bayer (PHAB) Awards at CHEST Annual Meeting 2019 - BioSpace - October 22nd, 2019 [October 22nd, 2019]
- The Epidemic Of The Metabolic Syndrome Among The Palestinians In The G | DMSO - Dove Medical Press - October 22nd, 2019 [October 22nd, 2019]
- Optina Diagnostics and the Montreal Heart Institute Partner to Develop a New Biomarker for Atherosclerosis - PRNewswire - October 22nd, 2019 [October 22nd, 2019]
- Even With Same Diagnosis, Women Get Half the Heart Attack Treatments as Men - AJMC.com Managed Markets Network - October 22nd, 2019 [October 22nd, 2019]
- Eva Dickerman, Andrew Weil - The New York Times - October 22nd, 2019 [October 22nd, 2019]
- EHR vendor Veradigm and partners creating new shared data tools for researchers - Healthcare IT News - October 22nd, 2019 [October 22nd, 2019]
- Evolocumab Well-tolerated as Add-on for Hypercholesterolemia Therapy - DocWire News - October 22nd, 2019 [October 22nd, 2019]
- Deborah Heart and Lung Center announces affiliation with Cleveland Clinic Heart & Vascular Institute - Health Essentials from Cleveland Clinic - October 22nd, 2019 [October 22nd, 2019]
- New Registry to Provide Insight into STEMI Occurrence, Treatment in North India | - Diagnostic and Interventional Cardiology - October 22nd, 2019 [October 22nd, 2019]
- Finding Your Best Fit in Cardiology - TCTMD - October 22nd, 2019 [October 22nd, 2019]
- Cardiology team expands to meet community need - The Union of Grass Valley - October 22nd, 2019 [October 22nd, 2019]
- Deaths After Ablation of Atrial Fibrillation 'Concerning' in Real-World Analysis - TCTMD - November 1st, 2019 [November 1st, 2019]
- Cutler Family gifts $15 million to University Hospitals to transform mens health care - Newswise - November 1st, 2019 [November 1st, 2019]
- Troponin Increases After Elective PCI Tied to Complexity, Extent of CAD - TCTMD - November 1st, 2019 [November 1st, 2019]
- Caregiving and the Soul of Medicine - Medscape - November 1st, 2019 [November 1st, 2019]
- STEMI Mortality Unaffected by Weekend, Weeknight, or Holiday Admission in France - TCTMD - November 1st, 2019 [November 1st, 2019]
- Cardiva Medical publishes positive results from the AMBULATE pivotal study Cardiology2.0 - Cardiology2.0 - November 1st, 2019 [November 1st, 2019]
- Gaps in Access to TAVR and SAVR: 'Something Needs to Be Done' - TCTMD - November 1st, 2019 [November 1st, 2019]
- Cardiva Medical Announces Publication of Data From the AMBULATE Pivotal Study in the Journal of the American College of Cardiology: Clinical... - November 1st, 2019 [November 1st, 2019]
- Raymond James 4 Analyst Favorite Health Care Picks With Huge Upside Potential - 24/7 Wall St. - November 7th, 2019 [November 7th, 2019]
- Global Computed Tomography (CT) Scanners Devices and Equipment Market Report 2020: Major Players are GE Healthcare, Koninklijke Philips, Hitachi,... - November 7th, 2019 [November 7th, 2019]